 Jared Greenberg
Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 7 | 2020 | 157 | 3.060 |
Why?
| | Critical Illness | 6 | 2021 | 125 | 2.590 |
Why?
| | Physicians | 3 | 2021 | 120 | 2.170 |
Why?
| | Family | 3 | 2021 | 111 | 1.660 |
Why?
| | Immunocompromised Host | 2 | 2018 | 55 | 1.280 |
Why?
| | Staphylococcal Infections | 5 | 2020 | 176 | 1.260 |
Why?
| | Hospital Mortality | 3 | 2020 | 192 | 1.220 |
Why?
| | Neoplasms | 2 | 2020 | 280 | 1.100 |
Why?
| | Critical Care | 4 | 2021 | 234 | 1.010 |
Why?
| | Intensive Care Units | 5 | 2021 | 316 | 0.950 |
Why?
| | Bacteremia | 4 | 2020 | 122 | 0.860 |
Why?
| | Staphylococcus aureus | 3 | 2019 | 87 | 0.850 |
Why?
| | Patient Advocacy | 1 | 2019 | 17 | 0.770 |
Why?
| | Hematologic Neoplasms | 2 | 2016 | 23 | 0.760 |
Why?
| | Anxiety | 1 | 2021 | 162 | 0.750 |
Why?
| | Hospitals, Low-Volume | 1 | 2018 | 7 | 0.720 |
Why?
| | Hospitals, High-Volume | 1 | 2018 | 10 | 0.720 |
Why?
| | Tracheostomy | 1 | 2018 | 28 | 0.710 |
Why?
| | Ventilator Weaning | 1 | 2018 | 33 | 0.700 |
Why?
| | Communication | 1 | 2019 | 129 | 0.690 |
Why?
| | Stress, Psychological | 1 | 2021 | 281 | 0.680 |
Why?
| | Patient Care Team | 1 | 2019 | 153 | 0.660 |
Why?
| | Adult | 12 | 2021 | 9779 | 0.640 |
Why?
| | Chronic Disease | 1 | 2019 | 544 | 0.640 |
Why?
| | Organ Dysfunction Scores | 1 | 2016 | 8 | 0.630 |
Why?
| | HIV Infections | 2 | 2016 | 951 | 0.620 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2016 | 12 | 0.600 |
Why?
| | Depression | 1 | 2021 | 516 | 0.590 |
Why?
| | Humans | 20 | 2021 | 31481 | 0.580 |
Why?
| | Middle Aged | 13 | 2021 | 11209 | 0.580 |
Why?
| | Respiration, Artificial | 3 | 2021 | 116 | 0.570 |
Why?
| | Rheumatic Diseases | 1 | 2016 | 61 | 0.550 |
Why?
| | Immunosuppressive Agents | 1 | 2016 | 163 | 0.540 |
Why?
| | Decision Making | 3 | 2021 | 232 | 0.530 |
Why?
| | Immune System Diseases | 1 | 2014 | 1 | 0.530 |
Why?
| | Aged | 11 | 2021 | 10295 | 0.500 |
Why?
| | Algorithms | 1 | 2016 | 412 | 0.490 |
Why?
| | Male | 13 | 2021 | 17583 | 0.470 |
Why?
| | Female | 13 | 2021 | 18253 | 0.460 |
Why?
| | Cross Infection | 1 | 2011 | 293 | 0.360 |
Why?
| | Retrospective Studies | 7 | 2018 | 3591 | 0.350 |
Why?
| | Cytokines | 3 | 2020 | 364 | 0.350 |
Why?
| | Hospitalization | 3 | 2021 | 359 | 0.330 |
Why?
| | Chicago | 2 | 2019 | 955 | 0.280 |
Why?
| | Influenza, Human | 2 | 2016 | 52 | 0.280 |
Why?
| | Prognosis | 2 | 2020 | 1028 | 0.280 |
Why?
| | Length of Stay | 2 | 2018 | 377 | 0.280 |
Why?
| | Proportional Hazards Models | 2 | 2018 | 390 | 0.280 |
Why?
| | Age Factors | 2 | 2018 | 943 | 0.270 |
Why?
| | Severity of Illness Index | 2 | 2018 | 1240 | 0.230 |
Why?
| | Th2 Cells | 2 | 2019 | 30 | 0.220 |
Why?
| | Th17 Cells | 2 | 2019 | 33 | 0.220 |
Why?
| | Immunity | 1 | 2020 | 23 | 0.210 |
Why?
| | Body Temperature | 1 | 2020 | 74 | 0.210 |
Why?
| | Uncertainty | 1 | 2020 | 7 | 0.200 |
Why?
| | Health Personnel | 1 | 2021 | 108 | 0.200 |
Why?
| | ROC Curve | 2 | 2018 | 153 | 0.190 |
Why?
| | Aged, 80 and over | 3 | 2019 | 5234 | 0.190 |
Why?
| | Logistic Models | 2 | 2018 | 479 | 0.190 |
Why?
| | Professional-Family Relations | 1 | 2019 | 29 | 0.190 |
Why?
| | Pandemics | 1 | 2021 | 203 | 0.190 |
Why?
| | Serum Bactericidal Test | 1 | 2018 | 2 | 0.180 |
Why?
| | United States | 3 | 2021 | 2539 | 0.180 |
Why?
| | Multilevel Analysis | 1 | 2018 | 8 | 0.180 |
Why?
| | Eosinophils | 1 | 2019 | 47 | 0.180 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2018 | 26 | 0.180 |
Why?
| | Lymphocyte Count | 1 | 2018 | 35 | 0.180 |
Why?
| | Immunity, Innate | 1 | 2019 | 97 | 0.180 |
Why?
| | Public Policy | 1 | 2018 | 6 | 0.180 |
Why?
| | Social Capital | 1 | 2018 | 4 | 0.170 |
Why?
| | Th1 Cells | 1 | 2018 | 35 | 0.170 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 156 | 0.170 |
Why?
| | Social Class | 1 | 2018 | 71 | 0.170 |
Why?
| | Flow Cytometry | 1 | 2018 | 217 | 0.170 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2018 | 56 | 0.170 |
Why?
| | Homeless Persons | 1 | 2018 | 23 | 0.170 |
Why?
| | Risk Factors | 3 | 2015 | 2664 | 0.170 |
Why?
| | Odds Ratio | 1 | 2018 | 327 | 0.160 |
Why?
| | Social Environment | 1 | 2018 | 93 | 0.160 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 362 | 0.160 |
Why?
| | Pilot Projects | 1 | 2018 | 455 | 0.160 |
Why?
| | APACHE | 1 | 2016 | 32 | 0.160 |
Why?
| | Sex Factors | 1 | 2018 | 542 | 0.160 |
Why?
| | Quality of Life | 1 | 2021 | 663 | 0.150 |
Why?
| | Virus Diseases | 1 | 2016 | 15 | 0.150 |
Why?
| | Case-Control Studies | 1 | 2018 | 687 | 0.150 |
Why?
| | Residence Characteristics | 1 | 2018 | 226 | 0.150 |
Why?
| | International Classification of Diseases | 1 | 2016 | 25 | 0.150 |
Why?
| | Coinfection | 1 | 2016 | 33 | 0.150 |
Why?
| | Body Mass Index | 1 | 2018 | 458 | 0.150 |
Why?
| | Bacterial Infections | 1 | 2016 | 71 | 0.150 |
Why?
| | Organ Transplantation | 1 | 2016 | 43 | 0.150 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2015 | 20 | 0.140 |
Why?
| | Mental Disorders | 1 | 2018 | 206 | 0.140 |
Why?
| | Databases, Factual | 1 | 2016 | 391 | 0.130 |
Why?
| | Antioxidant Response Elements | 1 | 2013 | 1 | 0.130 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2013 | 2 | 0.130 |
Why?
| | Pulmonary Alveoli | 1 | 2013 | 24 | 0.130 |
Why?
| | Time Factors | 1 | 2018 | 1902 | 0.120 |
Why?
| | Oxidative Stress | 1 | 2013 | 140 | 0.120 |
Why?
| | Georgia | 1 | 2011 | 16 | 0.110 |
Why?
| | Community-Acquired Infections | 1 | 2011 | 77 | 0.110 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2011 | 151 | 0.110 |
Why?
| | Acute Disease | 1 | 2011 | 254 | 0.100 |
Why?
| | HIV-1 | 1 | 2013 | 446 | 0.100 |
Why?
| | Prospective Studies | 2 | 2020 | 1934 | 0.070 |
Why?
| | Infant | 2 | 2016 | 642 | 0.060 |
Why?
| | Child, Preschool | 2 | 2016 | 786 | 0.060 |
Why?
| | Infant, Newborn | 2 | 2016 | 754 | 0.060 |
Why?
| | Treatment Outcome | 1 | 2011 | 3910 | 0.060 |
Why?
| | Child | 2 | 2016 | 1572 | 0.050 |
Why?
| | Fever | 1 | 2020 | 38 | 0.050 |
Why?
| | Shock, Septic | 1 | 2020 | 65 | 0.050 |
Why?
| | Antigens, CD1d | 1 | 2019 | 3 | 0.050 |
Why?
| | Interleukin-5 | 1 | 2019 | 10 | 0.050 |
Why?
| | Interleukin-13 | 1 | 2019 | 9 | 0.050 |
Why?
| | Pulmonary Edema | 1 | 2019 | 14 | 0.050 |
Why?
| | Netherlands | 1 | 2018 | 9 | 0.050 |
Why?
| | Adolescent | 2 | 2016 | 2667 | 0.040 |
Why?
| | Young Adult | 2 | 2016 | 2277 | 0.040 |
Why?
| | Hypersensitivity | 1 | 2019 | 54 | 0.040 |
Why?
| | Neutrophils | 1 | 2019 | 133 | 0.040 |
Why?
| | Lung | 1 | 2019 | 171 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2019 | 399 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 548 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 467 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 580 | 0.040 |
Why?
| | Animals | 2 | 2019 | 5312 | 0.040 |
Why?
| | Asthma | 1 | 2019 | 182 | 0.040 |
Why?
| | Influenza Vaccines | 1 | 2015 | 14 | 0.040 |
Why?
| | Age Distribution | 1 | 2015 | 110 | 0.040 |
Why?
| | Survival Analysis | 1 | 2016 | 379 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2019 | 832 | 0.040 |
Why?
| | Hospitals | 1 | 2015 | 142 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2015 | 139 | 0.030 |
Why?
| | Mice | 1 | 2019 | 1894 | 0.030 |
Why?
| | Quinones | 1 | 2013 | 1 | 0.030 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2013 | 1 | 0.030 |
Why?
| | Tight Junction Proteins | 1 | 2013 | 1 | 0.030 |
Why?
| | Sulfoxides | 1 | 2013 | 6 | 0.030 |
Why?
| | Thiocyanates | 1 | 2013 | 3 | 0.030 |
Why?
| | Isothiocyanates | 1 | 2013 | 5 | 0.030 |
Why?
| | Claudins | 1 | 2013 | 5 | 0.030 |
Why?
| | Occludin | 1 | 2013 | 13 | 0.030 |
Why?
| | Zonula Occludens-1 Protein | 1 | 2013 | 18 | 0.030 |
Why?
| | Rats, Transgenic | 1 | 2013 | 20 | 0.030 |
Why?
| | Glutathione | 1 | 2013 | 31 | 0.030 |
Why?
| | Anticarcinogenic Agents | 1 | 2013 | 18 | 0.030 |
Why?
| | RNA Interference | 1 | 2013 | 42 | 0.030 |
Why?
| | Comorbidity | 1 | 2015 | 562 | 0.030 |
Why?
| | Incidence | 1 | 2016 | 829 | 0.030 |
Why?
| | Down-Regulation | 1 | 2013 | 134 | 0.030 |
Why?
| | Cohort Studies | 1 | 2018 | 2014 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2013 | 371 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2013 | 802 | 0.030 |
Why?
| | Rats | 1 | 2013 | 966 | 0.030 |
Why?
|
|
Greenberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|